Moderna Aims for FDA Approval of RSV Vaccine

  moderna-aims-for-fda-approval-of-rsv-vaccine.html
  Food and Wine on Wed, Feb 18th, 2026 by KIRO-TV
      Locale: UNITED STATES

BETHESDA, Md. - February 18th, 2026 - Moderna, a biotechnology company that rose to prominence during the COVID-19 pandemic, is on the cusp of a significant expansion of its vaccine offerings. The company anticipates imminent approval from the Food and Drug Administration (FDA) for its updated respiratory syncytial virus (RSV) vaccine, mRNA-1369, targeting older adults. This development comes as Moderna strategically shifts its focus from solely COVID-19 vaccines to a broader range of preventative healthcare solutions.

RSV, a common respiratory virus, typically causes mild, cold-like symptoms. However, in vulnerable populations - particularly infants and older adults - it can lead to severe illness, hospitalization, and even death. The need for an effective RSV vaccine has been a longstanding public health priority, and Moderna's mRNA-1369 has demonstrated promising results in clinical trials, exhibiting both strong efficacy and a favorable safety profile.

"We anticipate approval in the coming weeks, and then we'll ramp up commercial production in anticipation of availability for the upcoming fall season," stated Moderna CEO Stephane Bancel during a recent investor call. The fall season is strategically important, as RSV infections typically surge during the colder months, making preventative vaccination crucial for protecting vulnerable individuals before the peak of the season.

While Moderna's COVID-19 vaccine continues to be a significant revenue driver, the company is actively diversifying its product pipeline. The shift reflects a broader industry trend - a move away from the emergency response mode of the pandemic to a more sustainable, long-term focus on preventative healthcare. The success of the mRNA technology platform, initially proven with the COVID-19 vaccine, is now being leveraged to address a wider spectrum of infectious diseases.

Beyond the imminent RSV approval, Moderna is aggressively pursuing the development of combination vaccines. These multi-valent shots are designed to provide protection against multiple respiratory illnesses simultaneously, offering convenience for patients and potentially increasing vaccination rates. Bancel revealed that Moderna is making significant progress on a combined RSV, influenza (flu), and COVID-19 vaccine.

"We're excited about the combination of RSV, flu, and COVID-19 vaccines," Bancel noted. "This is a natural evolution of our technology and a way to streamline preventative care for individuals, especially seniors." The potential benefits of a single shot protecting against three common respiratory viruses are considerable, reducing the burden on healthcare systems and minimizing the need for multiple appointments.

The development of these combination vaccines presents several technical challenges. Ensuring the efficacy and safety of multiple antigens within a single formulation requires precise engineering and rigorous testing. Furthermore, maintaining stable production and ensuring consistent dosages across all components is crucial. Moderna's expertise in mRNA technology and formulation, honed during the development of its COVID-19 vaccine, is expected to be a key asset in overcoming these hurdles.

According to Moderna's latest financial reports, while COVID-19 vaccine revenue remains substantial, the company is seeing a gradual decline as the pandemic transitions into an endemic phase. This anticipated decrease is driving the strategic shift towards RSV and other vaccines. The company is investing heavily in research and development, expanding manufacturing capacity, and building strategic partnerships to support its long-term growth.

The success of Moderna's RSV vaccine and the potential of its combination vaccines could significantly impact public health, particularly for older adults who are at higher risk of severe respiratory illnesses. The ability to proactively protect these vulnerable populations could reduce hospitalizations, improve quality of life, and lower healthcare costs. The FDA's upcoming decision on mRNA-1369 is therefore being closely watched by healthcare professionals, investors, and public health officials alike. The next few months promise to be pivotal for Moderna as it transitions from a pandemic-era vaccine manufacturer to a diversified, preventative healthcare company.